Well, it's been a lot longer wait than I ever expected. Maybe that will make it all the sweeter when it does come.
We own shares of this in several different accounts.
Here's what Value Line has to say about it currently:
"ADC Telecommunications is making some progress to restore profitability. In the face of steep spending reductions by the telecom carriers (its primary customers), ADC is continuing to lower both fixed and operating costs. In July, the company again reduced its pro forma quarterly break-even revenue point to $180 million (from $190 million in the April period).
However, there is no indication that ADC's end market is recovering. The company may benefit from increases in telephone carrier spending, stimulated by the FCC's August ruling to deregulate broadband, as well as from Defense Department contracts to build a global optical network. But the level and pace of investments in these new areas, as well as their impact on ADC's top line, remain uncertain. In the meantime, the Broadband Infrastructure and Access group (about 60% of total revenue) shows declining numbers, both sequentially and compared with last year's tally. Software systems and systems integration services are showing some improvement. and sequential increases. And in March ADC announced a multi-year contract with Deutsche Telecom for the Singl.eView billing system. But the company's focus on sales to major accounts will likely result in longer sales cycles. ADC's third-quarter sales came in slightly below our expectations, and we are at this time lowering our fiscal 2003 total by $15 million, to $765 million.
The company's improved financial resources give it added flexibility. With the recent addition of $400 million of convertible debt, cash increased to nearly $750 million. ADC now has ample resources to sustain operations for several years, as well as the option to expand through selective acquisitions.
ADCT shares are ranked Average (3) for the year ahead, but have long-term appeal. The timing for ADC's upside, however, will in large part depend on the strength and speed of an economic recovery.
Terese S. Fabian October 3, 2003"
Further, they expect ADCT to be break-even by next quarter and to have slight earnings starting the quarter after that. They have a lot of "purchasing power" with all that cash right now. If they do decide to go on an acquisition safari, they have plenty of ammo.
Best regards, Tom
Recent ADCT News
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan • GlobeNewswire Inc. • 05/01/2024 08:05:00 PM
- ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 • GlobeNewswire Inc. • 04/03/2024 11:00:00 AM
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- Mixed Futures Amidst Quiet Economic Schedule; Oil Prices Climb • IH Market News • 03/13/2024 11:03:39 AM
- ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit • GlobeNewswire Inc. • 03/06/2024 12:15:00 PM
- ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 03/05/2024 10:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 02:15:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:30:37 PM
- ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 01:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:15:54 PM
- ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards • GlobeNewswire Inc. • 01/04/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:00:30 PM
- ADC Therapeutics Provides Business Updates • GlobeNewswire Inc. • 01/04/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 01:10:56 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 01:05:58 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 01:04:44 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 01:00:16 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 12:59:46 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 12:58:50 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM